Zoetis.
American animal health company
- Reports this week
- 0
- Active events
- 0
- Connections
- 104
What's happening
Earlier this month
One to three months ago
-
FDA safety warnings have been issued, causing caution among clinicians.Some support3 reports1 development inside
-
Energy Transfer and Zoetis were mentioned as dividend growth stocks, with Getty Images providing the image source.Some support1 report
-
Market trends are showing consumer spending cuts due to inflation, strong demand for security solutions, and investor profit booking.Some support1 report
-
Saccaro joined Zoetis from GE HealthCare, having previously worked at Baxter International.Some support1 report
-
Morgan Stanley set a price target on Zoetis, while Citigroup reduced its price target on the shares. MarketBeat is reporting the average rating.Some support3 reports
-
Zoetis is headquartered in Parsippany, New Jersey.Some support2 reports
-
Zoetis was a top holding in the Platinum International Brands Fund, which is managed by Platinum Asset Management.Some support1 report
-
Christine Jenkins began her college education at the University of Chicago, received a lifetime achievement award from the AVMA, and served in senior leadership at Zoetis.Some support1 report
-
Phillip Kim advised investors of Zoetis on July 1, 2026.Some support1 report
-
The European Commission granted marketing authorization for a Zoetis vaccine addressing outbreaks in Spain and Poland.Some support1 report
Gone quiet
No new reports in 90+ days-
Safety warnings regarding product complications emerged involving the FDA and Zoetis on June 1, 2026.Some support3 reports1 development inside
-
FDA warnings caused a decline in sales for Zoetis products.Some support5 reports
-
A lawsuit was filed in New York City involving the company Zoetis.Some support5 reports1 development inside
-
FDA issued warnings regarding serious neurological complications involving Zoetis.Some support8 reports
-
Zoetis is facing a securities class action lawsuit in a US court.Some support9 reports
-
Stifel and Argus downgraded Zoetis stock following sharp declines on June 22, 2026.Some support1 report
-
Investor losses due to undisclosed product issues involving the FDA and Zoetis.Some support1 report
-
Zoetis allegedly misled investors regarding FDA warnings.Some support1 report
-
FDA safety warnings impacted product growth and market share, leading to a class action lawsuit handled by a Los Angeles law firm.Some support2 reports
-
Dr. Anna Hewison won the BVA Young Vet of the Year 2026 award, which was supported by Zoetis.Some support1 report
-
FDA safety warnings impacted product growth.Some support1 report
-
A law group has been engaged to represent investors who are suing Zoetis.Some support1 report
-
Zoetis and Sandoz Group AG Sponsored ADR are both considered stocks in the Medical - Drugs sector.Some support2 reports1 development inside
-
Phibro acquired Zoetis' MFA business, and JPMorgan analysts raised price targets and upgraded stock.Speculative1 report
-
Phibro Animal Health announced the integration of Zoetis' medicated feed additive portfolio on August 29, 2025.Some support1 report
-
Wedgewood Partners highlighted Zoetis stock on July 21, 2025, noting potential benefits from Trump-era tariffs.Some support1 report
-
Merck's pending drug is attracting veterinarian interest, while Stifel downgraded Zoetis stock to Hold.Speculative1 report
-
On June 27, 2025, Zoetis reported no slowdown in FDA review timelines, Amazon entered pet medication sales, and financial analysts questioned market trends.Speculative1 report
-
Zoetis appointed Kristin Peck as CEO and Wetteny Joseph as CFO on July 1, 2025.Speculative1 report
-
StockStory covered EXL in its research reports, alongside historical context regarding the Pfizer/Zoetis spin-off.Speculative1 report
-
Zoetis was spun off from Pfizer, and Nvidia generated a market-beating return of 1545%.Speculative1 report
-
SGIOY reported more impressive earnings estimate revisions on July 7, 2025.Speculative1 report
-
Phibro's MFA portfolio grew while Zoetis' MFA portfolio exceeded expectations on August 28, 2025.Some support1 report1 development inside
-
Zoetis and Merck are leading players in the equine healthcare market.Speculative1 report
-
Stifel downgraded Zoetis stock rating on July 17, 2025.Some support4 reports
-
Both Exact Sciences and Zoetis reported positive Earnings ESP on July 18, 2025.Some support1 report
-
Argus trimmed its price target on Zoetis stock on July 19, 2025.Some support1 report
-
Elanco, Zoetis, and Boehringer Ingelheim are noted for their leadership in the veterinary dermatology market.Some support1 report
-
Elanco's Zenrelia is now competing in the market against Zoetis' Apoquel.Some support2 reports1 development inside
-
USANA Health Sciences has better valuation metrics than Zoetis.Some support1 report
-
Reuters reported on the financial performance of Zoetis on August 5, 2025.Some support1 report
-
Scott Cenci previously worked at Genmab, Biogen, Zoetis, and Pfizer.Some support1 report
-
Zoetis reported business results on August 6, 2025, noting a 4% year-over-year revenue increase in the U.S. segment and FDA approval of a new indication for Simparica Trio.Some support1 report
-
Bank of America analyst questioned Zoetis regarding competitive dynamics on August 13, 2025.Some support2 reports
-
Zoetis stock underperformed the broader market on August 11, 2025.Some support3 reports
-
Barclays, BofA Securities, and Citigroup acted as joint book-running managers for a Zoetis offering filed with the SEC.Some support1 report
-
Zoetis representative will participate in a conference on August 27, 2025.Some support1 report
-
Pfizer spun off its animal health business, a move related to the animal health sector where Zoetis operates.Well supported13 reports
-
Zoetis is seeking expansion opportunities in various global markets.Some support3 reports
-
Rival company United Therapeutics outperformed Zoetis stock on September 5, 2025.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Zoetis this week
News at the entities that move Zoetis most-
European Commission StructuralA European Commission summit focused on strategic cooperation, minerals, and pivoting away from the United States toward the EU.Moves Zoetis
-
Merck OperationalEli Lilly, Novo Nordisk, and Merck are currently competing in the highly competitive GLP-1 obesity market.Moves Zoetis
-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Zoetis
-
Citigroup OperationalCitigroup provided analyst ratings and targets for Autodesk stock, which trades on Nasdaq.Moves Zoetis
-
Phibro StructuralPhibro and Dare Bioscience are both small-cap healthcare companies developing products for women's health in the United States.Moves Zoetis
-
Morgan Stanley OperationalFinancial firms including Morgan Stanley, Truist Financial, Jefferies Financial Group, and CIBC issued rating and price objective updates for Clearway Energy.Moves Zoetis
Connections
The 39 strongest of 104, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Merck Operational
Zoetis and Merck actively compete in the healthcare market, particularly in animal and equine health segments.
-
Pfizer Structural
Zoetis originated as a spun-off animal health division of Pfizer in 2013.
-
FDA Structural
The FDA regulates Zoetis, with its approvals, safety warnings, and oversight directly determining the company's product viability and market performance.
-
Phibro Structural
Phibro acquired Zoetis' MFA product portfolio and is integrating the business assets.
-
Citigroup Operational
Citigroup actively manages Zoetis's capital structure and provides market analysis on its shares.
-
European Commission Structural
Zoetis relies on the European Commission for marketing authorization to operate in the EU market.
-
Morgan Stanley Operational
Morgan Stanley provides financial analysis and sets price targets for Zoetis stock.
-
Elanco Operational
Elanco and Zoetis are direct competitors operating in the animal health and veterinary dermatology markets.
Show all 39 connections
-
Stifel Operational
Stifel provides financial ratings and analysis that influences the market perception and share price of Zoetis.
-
TD Cowen Operational
TD Cowen lowered its target price for Zoetis, indicating active financial analysis and influence.
-
Christine Jenkins Structural
Christine Jenkins served in a senior leadership role at Zoetis.
-
ARGUS Mentioned together
ARGUS provides financial ratings and analysis on Zoetis stock, influencing market perception.
-
Robbins Geller Rudman & Dowd LLP Transactional
The law firm is representing plaintiffs in a class action suit alleging securities law violations by Zoetis.
-
representative Transactional
Representative purchased shares of Zoetis stock.
-
Getty Images Transactional
Getty Images, a government agency, provided the image source for Zoetis.
-
Phillip Kim Operational
Phillip Kim provides advisory services to investors regarding Zoetis.
-
MarketBeat Mentioned together
MarketBeat provides financial ratings and coverage reports on Zoetis.
-
New Jersey Shared context
Zoetis is headquartered in New Jersey.
-
Poland Shared context
Zoetis operates within the context of Poland, specifically addressing disease outbreaks.
-
David J. Schwartz Mentioned together
David J. Schwartz was co-mentioned in an article discussing legal action against Zoetis.
-
Energy Transfer Mentioned together
The two companies are co-mentioned as dividend growth stocks.
-
New York City Shared context
Zoetis is facing investor class action claims and lawsuits originating in the jurisdiction of New York City.
-
Jazz Pharmaceuticals Operational
Market analysis compares the business strengths and financial performance of Jazz Pharmaceuticals and Zoetis.
-
Eli Lilly and Company Mentioned together
Both Eli Lilly and Zoetis are identified as companies operating within the pharmaceutical and biotech sectors.
-
Los Angeles Shared context
The company utilizes legal counsel based in Los Angeles for class action matters.
-
Livestock Shared context
Zoetis operates a business segment focused on the livestock health market.
-
Baxter International Mentioned together
A shared employee (Saccaro) worked at Baxter before moving to Zoetis.
-
Norges Bank Transactional
Norges Bank purchased a new position in Zoetis shares.
-
GE Healthcare Transactional
An individual previously employed by GE Healthcare joined Zoetis.
-
Spain Shared context
Zoetis operates within Spain, where its vaccines address local outbreaks.
-
New World Shared context
Zoetis products are utilized in the New World region to address screwworm issues.
-
New York Shared context
The company Zoetis was involved in a lawsuit concerning its securities that was filed in New York.
-
Parsippany Shared context
Zoetis is headquartered in Parsippany, NJ.
-
Bank of America Mentioned together
Both companies are mentioned in financial news, but the evidence does not show any direct interaction or coupling between them.
-
Michael Burry Operational
Michael Burry has publicly indicated a long position in Zoetis stock.
-
Steven Feldman Mentioned together
The single snapshot evidence is too vague to establish a direct relationship between Steven Feldman and Zoetis.
-
New York Shared context
Zoetis is mentioned in connection with a class action lawsuit, implying a legal context.
-
Pennsylvania Shared context
Zoetis maintains law offices in Bensalem, which is located within the geographic context of Pennsylvania.
-
Michael Albert Mentioned together
The provided evidence does not establish any observable relationship between Michael Albert and Zoetis.
History
Events by the month they beganSeptember 2026
1 eventAugust 2026
6 events- Airvet announced support for HABRI research.
- Energy Transfer and Zoetis were mentioned as dividend growth stocks, with Getty Images providing the image source.
- Market trends are showing consumer spending cuts due to inflation, strong demand for security solutions, and investor profit booking.
- Saccaro joined Zoetis from GE HealthCare, having previously worked at Baxter International.
- Morgan Stanley set a price target on Zoetis, while Citigroup reduced its price target on the shares. MarketBeat is reporting the average rating.
- Zoetis is headquartered in Parsippany, New Jersey.
July 2026
4 events- Zoetis was a top holding in the Platinum International Brands Fund, which is managed by Platinum Asset Management.
- Christine Jenkins began her college education at the University of Chicago, received a lifetime achievement award from the AVMA, and served in senior leadership at Zoetis.
- Phillip Kim advised investors of Zoetis on July 1, 2026.
- The European Commission granted marketing authorization for a Zoetis vaccine addressing outbreaks in Spain and Poland.
Show 1 earlier month
June 2026
41 events- FDA safety warnings have been issued, causing caution among clinicians.
- Safety warnings regarding product complications emerged involving the FDA and Zoetis on June 1, 2026.
- FDA warnings caused a decline in sales for Zoetis products.
- A lawsuit was filed in New York City involving the company Zoetis.
- FDA issued warnings regarding serious neurological complications involving Zoetis.
- Zoetis is facing a securities class action lawsuit in a US court.
- Stifel and Argus downgraded Zoetis stock following sharp declines on June 22, 2026.
- Investor losses due to undisclosed product issues involving the FDA and Zoetis.
- Zoetis allegedly misled investors regarding FDA warnings.
- FDA safety warnings impacted product growth and market share, leading to a class action lawsuit handled by a Los Angeles law firm.
- Dr. Anna Hewison won the BVA Young Vet of the Year 2026 award, which was supported by Zoetis.
- FDA safety warnings impacted product growth.
- A law group has been engaged to represent investors who are suing Zoetis.
- Zoetis and Sandoz Group AG Sponsored ADR are both considered stocks in the Medical - Drugs sector.
- Phibro acquired Zoetis' MFA business, and JPMorgan analysts raised price targets and upgraded stock.
- Phibro Animal Health announced the integration of Zoetis' medicated feed additive portfolio on August 29, 2025.
- Wedgewood Partners highlighted Zoetis stock on July 21, 2025, noting potential benefits from Trump-era tariffs.
- Merck's pending drug is attracting veterinarian interest, while Stifel downgraded Zoetis stock to Hold.
- On June 27, 2025, Zoetis reported no slowdown in FDA review timelines, Amazon entered pet medication sales, and financial analysts questioned market trends.
- Zoetis appointed Kristin Peck as CEO and Wetteny Joseph as CFO on July 1, 2025.
- StockStory covered EXL in its research reports, alongside historical context regarding the Pfizer/Zoetis spin-off.
- Zoetis was spun off from Pfizer, and Nvidia generated a market-beating return of 1545%.
- SGIOY reported more impressive earnings estimate revisions on July 7, 2025.
- Phibro's MFA portfolio grew while Zoetis' MFA portfolio exceeded expectations on August 28, 2025.
- Zoetis and Merck are leading players in the equine healthcare market.
- Stifel downgraded Zoetis stock rating on July 17, 2025.
- Both Exact Sciences and Zoetis reported positive Earnings ESP on July 18, 2025.
- Argus trimmed its price target on Zoetis stock on July 19, 2025.
- Elanco, Zoetis, and Boehringer Ingelheim are noted for their leadership in the veterinary dermatology market.
- Elanco's Zenrelia is now competing in the market against Zoetis' Apoquel.
- USANA Health Sciences has better valuation metrics than Zoetis.
- Reuters reported on the financial performance of Zoetis on August 5, 2025.
- Scott Cenci previously worked at Genmab, Biogen, Zoetis, and Pfizer.
- Zoetis reported business results on August 6, 2025, noting a 4% year-over-year revenue increase in the U.S. segment and FDA approval of a new indication for Simparica Trio.
- Bank of America analyst questioned Zoetis regarding competitive dynamics on August 13, 2025.
- Zoetis stock underperformed the broader market on August 11, 2025.
- Barclays, BofA Securities, and Citigroup acted as joint book-running managers for a Zoetis offering filed with the SEC.
- Zoetis representative will participate in a conference on August 27, 2025.
- Pfizer spun off its animal health business, a move related to the animal health sector where Zoetis operates.
- Zoetis is seeking expansion opportunities in various global markets.
- Rival company United Therapeutics outperformed Zoetis stock on September 5, 2025.